Zimmer price target raised to $131 from $110 at Canaccord Canaccord raised its price target on Zimmer Holdings to $131 from $110 to reflect the acquisition of Biomet. The firm sees a massive new knee product cycle and believes Zimmer is positioned solidly in the global musculoskeletal and OrthoRecon industry. Canaccord maintains its Buy rating on the stock.
Zimmer downgraded to Hold from Buy at Brean Capital Brean Capital downgraded Zimmer to Hold saying uncertainty over 2016 earnings potential following the Biomet acquisition is likely to linger for several quarters. Brean sees little room for multiple expansion pending greater clarity.